Fig. 3: Antibody levels against S were higher for BNT162b2 than CoronaVac in adolescents. | Nature Communications

Fig. 3: Antibody levels against S were higher for BNT162b2 than CoronaVac in adolescents.

From: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents

Fig. 3

Humoral and cellular immunogenicity was compared between vaccines in adolescents at 21-28 days after 1 dose and 28 days after 2 doses. a There were lower humoral responses after CC than BB as measured by S IgG (adolescent CC N = 116, adolescent BB N = 103) (GM OD450 0.54 vs 1.21; GMR 0.44, 95% CI 0.40–0.49), S-RBD IgG (adolescent CC N = 119, adolescent BB N = 104) (GM OD450 1.20 vs 2.64; GMR 0.46, 95% CI 0.41-0.50), sVNT (adolescent CC N = 119, adolescent BB N = 104) (GM % inhibition 71.2% vs 97.1%; GMR 0.73, 95% CI 0.68-0.79), PRNT90 (adolescent CC N = 64, adolescent BB N = 60) (GM PRNT90 9.58 vs 115; GMR 0.08, 95% CI 0.07–0.11), PRNT50 (adolescent CC N = 64, adolescent BB N = 60) (GM PRNT50 28.0 vs 331; GMR 0.08, 95% CI 0.07–0.11), S IgG avidity index (adolescent CC N = 109, adolescent BB N = 103) (GM % avidity 20.5% vs 29.7%; GMR 0.69, 95% CI 0.63–0.76) and S IgG FcγRIIIa-binding (adolescent CC N = 116, adolescent BB N = 103) (GM OD450 0.75 vs 2.07; GMR 0.36, 95% CI 0.31–0.42) (all P < 0.0001). Most outcomes except S IgG avidity were also lower in C compared to B. b Cellular immunogenicity outcomes were similar between vaccine types except for the S-specific IL-2+CD4+ T cell response (adolescent CC N = 60, adolescent BB N = 56), which was lower after CC (GM % T cells 0.015% vs 0.032%; GMR 0.45, 95% CI 0.28-0.72) (P = 0.001). Nucleocapsid (N) and membrane (M)-specific T cell responses were not compared since only CC but not BB had induced non-spike responses, as expected. Data labels and centre lines show GM estimates, and error bars show 95% CI. P-values were derived from two-tailed unpaired t test after natural logarithmic transformation. GM geometric mean, GMR geometric mean ratio, CI confidence interval, B 1 dose of BNT162b2, BB 2 doses of BNT162b2, C 1 dose of CoronaVac, CC 2 doses of CoronaVac, S spike protein, RBD receptor-binding domain, sVNT surrogate virus neutralisation test, PRNT plaque reduction neutralisation test, FcγRIIIa Fcγ receptor IIIa, IFN-γ interferon-γ, IL-2 interleukin-2. ***P < 0.001; ****P < 0.0001.

Back to article page